ストックスクリーナーアプリを入手
85.43
0.31%
0.26
プレマーケット:
85.93
0.50
+0.59%
Alcon Inc (ALC) 最新ニュース
BofA Securities lowers Alcon stock price target after Q1 results By Investing.com - Investing.com South Africa
BofA Securities lowers Alcon stock price target after Q1 results - Investing.com Australia
Alcon Stock Rated Buy by BTIG Following TRYPTYR Approval - MSN
Refractive Surgery Market Is Booming So Rapidly 2025-2032 - openPR.com
Alcon up 4% as FDA approves Tryptyr drops for dry eye - MSN
Alcon gains FDA approval of Tryptyr in DED - The Pharma Letter
BTIG maintains Alcon $99 target, upbeat on TRYPTYR launch By Investing.com - Investing.com Canada
Citi maintains Buy on Alcon, price target CHF99 after FDA nod By Investing.com - Investing.com South Africa
Citi maintains Buy on Alcon, price target CHF99 after FDA nod - Investing.com India
Alcon Inc. (ALC)’s TRYPTYR Wins FDA Nod for Dry Eye Disease - MSN
FDA Approves Alcon’s Tryptyr for Dry Eye Disease - Managed Healthcare Executive
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019 - Benzinga
Alcon Stock Rises Following the FDA Approval of TRYPTYR - MSN
US FDA approves Alcon's new dry-eye drug - Reuters
FDA approves Alcon’s Tryptyr (AR-15512) for signs and symptoms of dry eye disease - Ophthalmology Times
Alcon receives FDA approval for Tryptyr to treat dry eye disease - World Pharmaceutical Frontiers
FDA approves Alcon’s TRYPTYR for Dry Eye Disease treatment By Investing.com - Investing.com South Africa
BTIG maintains Alcon $99 target, upbeat on TRYPTYR launch - Investing.com
Alcon’s Strategic Initiatives and Valuation Justify Buy Rating with $99 Price Target - TipRanks
US FDA Approves Alcon's Dry Eye Disease Treatment - marketscreener.com
US FDA approves Alcon’s new dry-eye drug - The Mighty 790 KFGO
Alcon (ALC) Gains FDA Approval for Innovative Dry Eye Treatment - GuruFocus
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic s - GuruFocus
Alcon (ALC) Gains FDA Nod for Innovative Dry Eye Treatment | ALC Stock News - GuruFocus
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease | ALC Stock News - GuruFocus
FDA approves Alcon’s TRYPTYR for Dry Eye Disease treatment - Investing.com
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease - marketscreener.com
Gordon Schanzlin New Vision Institute First in Region to Offer Groundbreaking Alcon Sitemap Technology for Personalized Vision Correction - GlobeNewswire Inc.
BTIG maintains Alcon stock Buy rating, $99 target By Investing.com - Investing.com South Africa
DOJ Requires Keysight to Shed Spirent Units Before $1.57 Billion Acquisition Proceeds - PYMNTS.com
BTIG maintains Alcon stock Buy rating, $99 target - Investing.com
Turkey Contact Lens MarketCompetition, Forecast & Opportunities to 2030, Featuring Tech Contactlens, Diafarma, Alcon Laboratories, Diplomat Optics, Hoya Turkiye, ZEISS Turkiye, Keralens & more - Yahoo
U.S. Ophthalmic Photocoagulator Growth Trends and Forecasts 2025-2032 - GlobeNewswire Inc.
FTC Requests More Information on Alcon's $430 Million Acquisition of Lensar - PYMNTS.com
FTC Probing Alcon's $430M Lensar Deal - Law360
Stifel Nicolaus Reaffirms Their Buy Rating on Alcon (ALC) - The Globe and Mail
Eye care product makers Alcon, LENSAR get second request from US FTC - MLex
Alcon (ALC) Receives Upgrade to Buy from Kepler Cheuvreux | ALC Stock News - GuruFocus
Alcon Inc. (NYSE:ALC) Q1 2025 Earnings Call Transcript - MSN
Alcon (ALC): A Key Partner in Lifecore's Revenue Growth Strategy - GuruFocus
Alcon (ALC): A Key Partner in Lifecore's Revenue Growth Strategy | ALC Stock News - GuruFocus
Alcon (VTX:ALC) Strong Profits May Be Masking Some Underlying Issues - simplywall.st
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Alcon (ALC) - The Globe and Mail
Alcon's (VTX:ALC) Profits May Not Reveal Underlying Issues - Yahoo Finance
1.24%
大文字化:
|
ボリューム (24 時間):